'Immediate' Steps To Lower Drug Prices: The HHS Action Plan
Many of blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.
You may also be interested in...
Rep. Diana DeGette, new chair of US House Energy and Commerce Committee's Subcommittee on Oversight and Investigations, said insulin is a good example of problems with drug pricing and promised to call drug company CEOs to hearings.
Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.
DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.